Likewise, in our study, anti-angiogenic therapies showed remarkable antitumor activity in the phase I clinical trials and were associated with increased PFS, demonstrating the importance of p53-VEGF crosstalk in ovarian cancer tumorigenesis and development and the therapeutic advantage of VEGF inhibition in this cohort of patients. This evidence concerns the gene TP53 and ovarian cancer.